Home/Filings/4/0001493152-24-048950
4//SEC Filing

Cross John Harry III 4

Accession 0001493152-24-048950

CIK 0001106838other

Filed

Dec 4, 7:00 PM ET

Accepted

Dec 5, 9:55 PM ET

Size

5.5 KB

Accession

0001493152-24-048950

Insider Transaction Report

Form 4
Period: 2023-12-11
Cross John Harry III
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2023-12-111,4521,588 total
Footnotes (3)
  • [F1]On December 11, 2023, the Reporting Person was granted 1,452 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025.
  • [F2]Includes unvested restricted stock units.
  • [F3]All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.

Documents

1 file

Issuer

Sonnet BioTherapeutics Holdings, Inc.

CIK 0001106838

Entity typeother

Related Parties

1
  • filerCIK 0001806763

Filing Metadata

Form type
4
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 9:55 PM ET
Size
5.5 KB